

# HEALEY ALS Platform Trial

Weekly Q&A – June 16, 2022



## Healey Center

Sean M. Healey & AMG Center  
for ALS at Mass General




The AMG Foundation

# Guest Speaker

**Bruce Rosenblum**  
EAP Patient Advisory Committee Member



# The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



# Enrollment Updates (as of June 16, 2022)

- **77** individuals have signed informed consent
- **48** individuals have been randomized within Regimen E


*Thank You*

**This breakthrough trial would not be possible without your participation**

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

**Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality**

# 37 Sites Currently Activated for Regimen E



(as of 6/16/22)

*Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!*

- ✓ Lehigh Valley Health Network
- ✓ UC San Francisco
- ✓ Mass General Hospital
- ✓ Mayo Rochester
- ✓ University of Kansas
- ✓ University of Washington
- ✓ University of Maryland
- ✓ **✓ Vanderbilt University**
- ✓ California Pacific Medical Center
- ✓ Northwestern University
- ✓ Virginia Commonwealth University
- ✓ University of Nebraska
- ✓ Washington University
- ✓ Wake Forest University
- ✓ Hospital for Special Care
- ✓ Saint Alphonsus Regional
- ✓ University of Massachusetts
- ✓ Duke University
- ✓ Barrow Neurological Institute
- ✓ Georgetown University
- ✓ Texas Neurology
- ✓ Beth Israel Deaconess Medical Center
- ✓ SUNY Upstate
- ✓ Spectrum Health
- ✓ Henry Ford Hospital
- ✓ Essentia Health
- ✓ University of Southern California
- ✓ University of South Florida
- ✓ University of Colorado
- ✓ Providence Brain and Spine
- ✓ University of Minnesota
- ✓ Loma Linda University
- ✓ University of Iowa
- ✓ Swedish Medical Center
- ✓ Ohio State University
- ✓ University of Cincinnati
- ✓ Thomas Jefferson University

# Checking Site Status Online

## List of Participating Sites

*Sites marked "Recruiting" are currently enrolling participants in regimen E.*

*Sites marked "Active, Not recruiting" are active in the platform (for example, they are following participants in regimens A-D) but are not enrolling new participants at this time. Most active sites are expected to start enrolling in regimen E soon.*

Site	State	Enrollment Status	Contact Information
Lehigh Valley Health Network	PA	Recruiting	<a href="#">Andrew Orzel</a> (610-402-9543)
Penn State Hershey	PA	Active, Not recruiting	<a href="#">Heidi Runk</a>



<https://bit.ly/3g2NZr5>

# Patient Navigation

## Central resource for people living with ALS



Catherine Small

Phone: 833-425-8257 (HALT ALS)

E-mail: [healeyalsplatform@mgh.harvard.edu](mailto:healeyalsplatform@mgh.harvard.edu)

Weekly webinar  
registration:



<https://bit.ly/3r6Nd2L>

ALS Link sign-up:



<https://bit.ly/3o2Ds3m>



Allison Bulat

### Upcoming Guest Speakers:

**June 23<sup>rd</sup>**- Jackie Whitesell, MD (Investigator at Saint Alphonsus Medical Center, Idaho)

**June 30<sup>th</sup>**- Gale Kittle, RN, MPH (Director, Outcomes Measurement Training)

**July 14<sup>th</sup>**- Eufrosina Young, MD (Investigator at SUNY Upstate, New York)



The ALS Association/Northeast ALS Consortium Educational Webinar

## Healey ALS Platform Trial Regimen E: A Participant's Guide

**Friday, June 17, 2022**  
5:00 - 6:00 PM EDT

The purpose of this webinar is to provide an overview of how SLS-005 (trehalose) may help to slow ALS and illustrate what potential participants can expect when enrolling in Regimen E of the Healey ALS Platform Trial. The presenters will review some of the unique aspects of the regimen related to the intravenous administration.

**Register Below:**



<https://bit.ly/3aeT5kc>

*Recording will later be available under  
"educational webinars" on neals.org*